Economics of biological therapies

descriptionPublicationkeyboard_double_arrow_right Article 21 Aug 2009 English Publisher:BMJJournal:BMJ, volume 339, pages b3276-b3276 (issn: 0959-8138, eissn: 1468-5833,

Copyright policy )

Authors: Christopher J, Kelly; Fraz A, Mir;

doi: 10.1136/bmj.b3276

pmid: 19700510

Economics of biological therapies

- Summary
- Subjects
- Metrics

Abstract

Demand for biological drugs is putting pressure on health budgets. Christopher Kelly and Fraz Mir examine why they are so expensive and what can be done to increase access

Related Organizations

Cambridge University Hospitals NHS Foundation Trust
United Kingdom
Addenbrooke's Hospital
United Kingdom
University of Cambridge
United Kingdom

Keywords

Biological Therapy, Drug Industry, Cost-Benefit Analysis, Commerce, Drugs, Generic, Humans, Delivery of Health Care, Drug Approval, Drug Costs, Forecasting

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	31
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%